Positive Results in Clinical Trial Testing Lupuzor

A Phase 2 clinical trial found that the investigational biologic drug Lupuzor lessened symptoms in some patients with lupus.  Improvements in arthritis and rash were seen among approximately two thirds of patients, though not significantly higher than those given a placebo.  The Food and Drug Administration has given the go-ahead for ImmuPharma to test the safety and effectiveness of Lupuzor in Phase 3 trials among a larger group of lupus patients.